Drug Profile

Protein free botulinum toxin A - Medytox

Alternative Names: Coretox

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medytox
Class Botulinum toxins; Muscle relaxants; Skin disorder therapies
Mechanism of Action Neuromuscular blocking agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Glabellar lines
Registered Muscle spasticity

Most Recent Events

09 Nov 2018 Medy-Tox completes a phase I/III trial in Muscle spasticity in South Korea (Injection) (NCT05164003)
09 Nov 2018 Medytox completes a phase III trial for Muscle spasticity in South Korea (Injection) (NCT03289702)
17 Jul 2017 Medy-Tox initiates a phase I/III trial in Muscle spasticity in South Korea (Injection) (NCT05164003)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com